Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors
摘要:
Novel N-9-arenethenyl purines, optimized potent dual Src/Abl tyrosine kinase inhibitors, are described. The key structural feature is a trans vinyl linkage at N-9 on the purine core which projects hydrophobic substituents into the selectivity pocket at the rear of the ATP site. Their synthesis was achieved through a Horner-Wadsworth-Emmons reaction of N-9-phosphorylmethylpurines and substituted benzaldehydes or Heck reactions between 9-vinyl purines and aryl halides. Most compounds are potent inhibitors of both Src and Abl kinase, and several possess good oral bioavailability. (C) 2008 Elsevier Ltd. All rights reserved.
[EN] This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use. [FR] La présente invention porte sur des composés représentés par la formule générale (I) dans laquelle les groupes de variables sont tels que définis dans la description, ainsi que sur leur préparation et utilisation.